Genprex, Inc. Files 8-K Report
Ticker: GNPX · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1595248
Sentiment: neutral
Topics: 8-K, SEC Filing, Pharmaceuticals
TL;DR
Genprex filed an 8-K on 10/23/25, check it for company updates.
AI Summary
Genprex, Inc. filed an 8-K on October 23, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Austin, TX, operates in the Pharmaceutical Preparations sector. The filing details are associated with accession number 0001437749-25-031572.
Why It Matters
This 8-K filing indicates that Genprex, Inc. is providing updates on its corporate activities and financial status to the SEC, which is important for investors to monitor company developments.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate events and financial information, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 001-38244 — SEC File Number (Identifies the company's filing history with the SEC.)
- 90-0772347 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- 0001437749-25-031572 (dollar_amount) — Accession Number
- October 23, 2025 (date) — Report Date
- Austin, TX (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific 'Other Events' are being reported by Genprex, Inc. in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the SIC code for Genprex, Inc. and what does it signify?
The SIC code is 2834, which corresponds to 'Pharmaceutical Preparations', indicating the company's industry.
When was Genprex, Inc. incorporated?
Genprex, Inc. was incorporated in Delaware.
What is the primary business address of Genprex, Inc.?
The principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the filing date of this Form 8-K?
The Form 8-K was filed on October 23, 2025.
Filing Stats: 1,390 words · 6 min read · ~5 pages · Grade level 16.4 · Accepted 2025-10-23 07:05:16
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20251021d_8k.htm (8-K) — 34KB
- 0001437749-25-031572.txt ( ) — 168KB
- gnpx-20251023.xsd (EX-101.SCH) — 3KB
- gnpx-20251023_def.xml (EX-101.DEF) — 12KB
- gnpx-20251023_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251023_pre.xml (EX-101.PRE) — 12KB
- gnpx20251021d_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 23, 2025, Genprex, Inc. ("Genprex" or the "Company") issued a press release announcing that its research collaborators will present positive preclinical data at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 at the Hynes Convention Center in Boston. The collaborators will present positive preclinical data from a study of Genprex's lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), for the treatment of ALK-EML4 positive non-small cell lung cancer ("NSCLC"). The presentation data describes that researchers evaluated tumor suppressor candidate 2 ("TUSC2") expression in several ALK+ cell lines and patient derived organoids ("PDOs"), both before and after exposure to quaratusugene ozeplasmid ("QO"). The studies indicate that QO mediated overexpression of TUSC2 significantly induced apoptosis in ALK+ cell lines and PDOs, as demonstrated by increase in caspase 3/7 activity of the cells, increased protein expression of pro-apoptotic markers, reduced colony formation ability of the cells, and increased DNA fragmentation. Furthermore, the abstract notes that researchers have observed a robust pro-apoptotic response in ALK+ NSCLC cell lines with acquired resistance to the ALK inhibitor, alectinib, resulting in reduced cell viability when treated with QO and alectinib in combination. To better understand how QO and alectinib work in combination, the abstract describes that researchers subcutaneously injected NCI-H2228 ALK+ cells into nude mice and when the tumors developed to approximately 100mm3, mice were randomized into 4 groups. Mice from group 1 were treated with vehicle control, group 2 were treated with QO (25ug/mouse, i.v., every three days), group 3 were treated with alectinib (0.5mg/kg/mouse, oral gavage, every day) and group 4 were treated with QO and alectinib in combination at the same concentration and frequency of dosin
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: October 23, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)